{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:32:15Z","timestamp":1790616735279,"version":"4.1.0"},"reference-count":35,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Background\/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a heterogeneous condition shaped by metabolic dysfunction, adipose tissue distribution, inflammatory activation, and body composition. Understanding how these factors interact across distinct clinical phenotypes is essential for improving diagnostic accuracy and risk stratification. This study aimed to compare metabolic, inflammatory, and elastographic profiles between MASLD subgroups defined by adipose tissue dysfunction (ATD) and obesity, and to identify pathways linking metabolic dysregulation to hepatic fibrosis. Methods: We conducted a cross-sectional observational study including 178 adult participants evaluated clinically, biochemically, and by bioimpedance and shear wave elastography. Participants ranged in age from 19 to 82 years. Patients were stratified into a non-MASLD control group and two MASLD subgroups: MASLD with ATD (G1) and MASLD with obesity (G2). Anthropometric data, lipid profile, glycemic markers, cytokines (IL-6, IL-10, TNF-\u03b1), liver stiffness, and non-invasive fibrosis indices were compared across groups using standard statistical testing. Results: Patients with MASLD showed higher liver stiffness, triglycerides, and IL-6\/IL-10 levels than controls. Between MASLD phenotypes, the ATD group (G1) exhibited a more inflammatory and dysmetabolic profile, with significantly higher triglycerides, IL-6 levels, neutrophil counts, and creatinine, alongside trends suggesting early sarcopenic changes. In contrast, the obese phenotype (G2) demonstrated greater hepatic structural involvement, including higher liver stiffness and BMI, AST\/ALT ratio and Diabetes (BARD) scores, despite more favorable inflammatory parameters. Several associations between liver stiffness, IL-6, and glycemic control approached but did not reach statistical significance. Conclusions: MASLD progression appears to follow two complementary but distinct mechanisms: an inflammatory, adipose dysfunction pathway dominated by IL-6 activation and early anabolic decline, and a metabolic-overload pathway driven by obesity. Phenotype-specific evaluation integrating inflammatory markers, metabolic indices, and elastographic parameters may improve risk stratification and inform personalized therapeutic strategies.<\/jats:p>","DOI":"10.3390\/nu17243940","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:43:46Z","timestamp":1765964626000},"page":"3940","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Refining MASLD Phenotypes: Clinical, Metabolic, and Elastographic Differences Between Adipose Tissue Dysfunction and Obesity-Driven Disease"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7626-1869","authenticated-orcid":false,"given":"Tudor","family":"Cosma","sequence":"first","affiliation":[{"name":"Regional Institute of Gastroenterology and Hepatology \u201cProf. Dr. Octavian Fodor\u201d, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2656-3234","authenticated-orcid":false,"given":"Lucretia","family":"Avram","sequence":"additional","affiliation":[{"name":"Department 5\u2014Medical Specialties, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, Geriatrics-Gerontology, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0231-2131","authenticated-orcid":false,"given":"Valer","family":"Donca","sequence":"additional","affiliation":[{"name":"Department 5\u2014Medical Specialties, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, Geriatrics-Gerontology, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Grosu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 5th Medical Clinic, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7451-1901","authenticated-orcid":false,"given":"Laurentiu","family":"Stoicescu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 5th Medical Clinic, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Buzdugan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 5th Medical Clinic, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0600-6097","authenticated-orcid":false,"given":"Andrada","family":"Nemes","sequence":"additional","affiliation":[{"name":"Intensive Care Unit Department 6, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0038-7084","authenticated-orcid":false,"given":"Andrei-Mihai","family":"Balan","sequence":"additional","affiliation":[{"name":"Intensive Care Unit Department 6, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-9670","authenticated-orcid":false,"given":"Dana","family":"Crisan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, 5th Medical Clinic, Clinical Municipal Hospital, Faculty of Medicine, \u201cIuliu Hatieganu\u201d University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1053\/j.gastro.2025.02.044","article-title":"Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis","volume":"169","author":"Younossi","year":"2025","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(2025). Reframing obesity and MASLD. Nat. Rev. Gastroenterol. Hepatol., 22, 147.","DOI":"10.1038\/s41575-025-01046-y"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ciardullo, S., Vergani, M., and Perseghin, G. (2023). Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment. J. Clin. Med., 12.","DOI":"10.3390\/jcm12175597"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., and Pliouta, L. (2025). The Triad of Risk: Linking MASLD, Cardiovascular Disease and Type 2 Diabetes; From Pathophysiology to Treatment. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020428"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Pais, R., and Maurel, T. (2021). Natural History of NAFLD. J. Clin. Med., 10.","DOI":"10.3390\/jcm10061161"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25724","DOI":"10.1038\/s41598-024-76922-9","article-title":"Prevalence of steatotic liver disease (MASLD, MetALD, ALD) and clinically significant fibrosis in US adolescents","volume":"14","author":"Shi","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the Burden of Nonalcoholic Fatty Liver Disease: Time for Action","volume":"37","author":"Younossi","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s13679-025-00637-9","article-title":"Metabolically Healthy Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Navigating the Controversies in Disease Development and Progression","volume":"14","author":"Koliaki","year":"2025","journal-title":"Curr. Obes. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2016-3628","article-title":"Effects of Metreleptin in Pediatric Patients with Lipodystrophy","volume":"102","author":"Brown","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.metabol.2018.11.009","article-title":"Metabolically healthy versus metabolically unhealthy obesity","volume":"92","author":"Iacobini","year":"2019","journal-title":"Metabolism"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Syed-Abdul, M.M. (2023). Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD. Metabolites, 14.","DOI":"10.3390\/metabo14010012"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3390\/livers4040047","article-title":"Progressive Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) from a Young Age Due to a Rare Genetic Disorder, Familial Partial Lipodystrophy: A Case Report and Review of the Literature","volume":"4","author":"Vorona","year":"2024","journal-title":"Livers"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Wang, J., Li, H., Niu, Q., Tao, Y., Zhao, X., Zeng, Z., and Dong, H. (2025). The role of the interleukin family in liver fibrosis. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1497095"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.52547\/ibj.3647","article-title":"Update on Non-Alcoholic Fatty Liver Disease-Associated Single Nucleotide Polymorphisms and Their Involvement in Liver Steatosis, Inflammation, and Fibrosis","volume":"26","author":"Astarini","year":"2022","journal-title":"Iran. Biomed. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s40164-024-00527-1","article-title":"The double-edged effects of IL-6 in liver regeneration, aging, inflammation, and diseases","volume":"13","author":"Wang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hep.31658","article-title":"Myeloid-Cell-Specific IL-6 Signaling Promotes MicroRNA-223-Enriched Exosome Production to Attenuate NAFLD-Associated Fibrosis","volume":"74","author":"Hou","year":"2021","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Duan, Y., Pan, X., Luo, J., Xiao, X., Li, J., Bestman, P.L., and Luo, M. (2022). Association of Inflammatory Cytokines with Non-Alcoholic Fatty Liver Disease. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880298"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jceh.2021.07.001","article-title":"Diabetes Mellitus Increases the Risk of Significant Hepatic Fibrosis in Patients with Non-alcoholic Fatty Liver Disease","volume":"12","author":"Chhabra","year":"2022","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"23362","DOI":"10.1038\/s41598-024-74098-w","article-title":"Identifying patient subgroups in MASLD and MASH-associated fibrosis: Molecular profiles and implications for drug development","volume":"14","author":"Verschuren","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2337\/dc09-1825","article-title":"Visceral Adiposity Index: A reliable indicator of visceral fat function associated with cardiometabolic risk","volume":"33","author":"Amato","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"730827","DOI":"10.1155\/2014\/730827","article-title":"Visceral adiposity index: An indicator of adipose tissue dysfunction","volume":"2014","author":"Amato","year":"2014","journal-title":"Int. J. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"bnaa004","DOI":"10.1210\/endrev\/bnaa004","article-title":"Metabolically Healthy Obesity","volume":"41","year":"2020","journal-title":"Endocr. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"111341","DOI":"10.1016\/j.intimp.2023.111341","article-title":"Interleukin-10 gene intervention ameliorates liver fibrosis by enhancing the immune function of natural killer cells in liver tissue","volume":"127","author":"Chen","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hep.23322","article-title":"Lack of interleukin-6\/glycoprotein 130\/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice","volume":"51","author":"Kroy","year":"2010","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"de Abreu, J.D.M.F., Azulay, R.S., Rodrigues, V., de Abreu, S.L.L., Tavares, M.d.G., Pinheiro, F.C.M., Neto, C.P.d.O., Andrade, C., Facundo, A., and S\u00e1, A.G. (2024). Predictors of Hepatic Fibrosis in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease. Biomedicines, 12.","DOI":"10.3390\/biomedicines12112542"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Cri\u015fan, D., Avram, L., Morariu-Barb, A., Grapa, C., Hiri\u015fcau, I., Cr\u0103ciun, R., Donca, V., and Neme\u015f, A. (2025). Sarcopenia in MASLD-Eat to Beat Steatosis, Move to Prove Strength. Nutrients, 17.","DOI":"10.3390\/nu17010178"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12937-025-01081-0","article-title":"Correlation of sarcopenia with progression of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease: A study from two cohorts in China and the United States","volume":"24","author":"Zhang","year":"2025","journal-title":"Nutr. J."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Wei, X., Liu, X., Zhao, J., Zhang, Y., Qiu, L., and Zhang, J. (2025). Association of sarcopenia and physical activity on the severity of metabolic dysfunction-associated steatotic liver disease among United States adults: NHANES 2017\u20132018. Front. Aging, 6.","DOI":"10.3389\/fragi.2025.1573170"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Chen, M., Cao, Y., Ji, G., and Zhang, L. (2023). Lean nonalcoholic fatty liver disease and sarcopenia. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1217249"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cmet.2024.10.008","article-title":"A blood-based biomarker panel for non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis","volume":"37","author":"Zhang","year":"2025","journal-title":"Cell Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"9639","DOI":"10.1038\/s41598-025-91013-z","article-title":"Development and validation of a scoring system to predict MASLD patients with significant hepatic fibrosis","volume":"15","author":"Long","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.jcmgh.2021.11.007","article-title":"TM6SF2\/PNPLA3\/MBOAT7 Loss-of-Function Genetic Variants Impact on NAFLD Development and Progression Both in Patients and in In Vitro Models","volume":"13","author":"Longo","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1080\/21645515.2020.1761203","article-title":"Different roles of interleukin 6 and interleukin 11 in the liver: Implications for therapy","volume":"16","author":"Widjaja","year":"2020","journal-title":"Hum. Vaccines Immunother."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/24\/3940\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:51:02Z","timestamp":1765965062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/17\/24\/3940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":35,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["nu17243940"],"URL":"https:\/\/doi.org\/10.3390\/nu17243940","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]}}}